argenex (NASDAQ:ARGX) Stock Purchase Reported by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in argenex stock on October 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

argenex Stock Performance

Shares of ARGX opened at $977.58 on Thursday. The stock has a fifty day moving average price of $927.22 and a two-hundred day moving average price of $859.56. The company has a market cap of $61.48 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 0.90 and a beta of 0.48. argenex SE has a 52-week low of $661.85 and a 52-week high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. The business had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. As a group, research analysts predict that argenex SE will post 28.41 EPS for the current fiscal year.

Institutional Trading of argenex

Hedge funds have recently added to or reduced their stakes in the business. Optas LLC lifted its holdings in argenex by 4.6% during the third quarter. Optas LLC now owns 250 shares of the company’s stock worth $240,000 after acquiring an additional 11 shares in the last quarter. Mather Group LLC. grew its stake in shares of argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after acquiring an additional 13 shares in the last quarter. Farther Finance Advisors LLC lifted its position in argenex by 3.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock worth $363,000 after buying an additional 13 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in argenex by 2.7% during the third quarter. Oppenheimer & Co. Inc. now owns 500 shares of the company’s stock valued at $479,000 after purchasing an additional 13 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of argenex by 2.8% in the 1st quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after buying an additional 14 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ARGX shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of argenex in a research note on Friday, September 25th. Wells Fargo & Company reduced their target price on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a report on Friday, October 23rd. Royal Bank Of Canada cut their price target on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 20th. Wedbush reduced their price objective on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. Finally, Jefferies Financial Group restated a “buy” rating on shares of argenex in a report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and an average target price of $1,158.76.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.